You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動|昆藥集團漲超6%子公司擬收購貝克浙江30%股權
格隆匯 08-15 10:56
格隆匯8月15日丨昆藥集團(600422.SH)漲超6%,報11.11元,成交4億元,總市值84.6億元。昆藥集團(600422.SH)公佈,公司的子公司昆明貝克諾頓製藥有限公司(“貝克諾頓”)擬出資人民幣約1213.48萬元向自然人王友昆購買其所持有的貝克諾頓(浙江)製藥有限公司(“貝克浙江”)15%股權;貝克諾頓擬出資人民幣約1213.48萬元向自然人鍾曉明購買其所持有的貝克浙江15%股權。此次交易完成後,貝克諾頓將持有貝克浙江100%股權。公告顯示,貝克諾頓製藥公司現有頭孢和青黴素類抗生素、消化系統用藥、青蒿素系列抗瘧藥等30多個產品,2016年度實現主營業務收入5915萬元、2017年度實現主營業務收入7016萬元、2018年實現主營業務收入7767萬元。此次交易目的是加快完成集團構建完整產業,促進集團生產銷售業務整合,降低生產運營成本,保持產品在市場中的競爭能力。(行情來源:富途證券)
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account